Interestingly, a stratification into sub-groups using a combination of IL-36α plus IL-36γ production provided a better prognostic outcome than when IL-36α or IL-36γ production only was evaluated in CRC patients. This evidence concerns the gene IL36A and colorectal carcinoma.